Absci Corp (ABSI)

Name: Absci Corp (ABSI) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Absci Corp (ABSI)

Stock Card

$8.95

$-0.09 (-1.00%)

As on 01-Sep-2026 11:37EDT

Market cap

$1,495 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

P/B Ratio

6.6

Div. Yield

0 %

Absci Corp (ABSI) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 8.75 High: 9.08

52 Week Range

Low: 2.24 High: 12.06

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.6 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.4
Debt to Equity

0
Book Value

$--
EPS

$-0.8
Face value

--
Shares outstanding

171,614,010

5 Years Aggregate

CFO

$-223.57 Mln

EBITDA

$-289.22 Mln

Net Profit

$-337.80 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Absci Corp (ABSI)	156.4	15.0	32.6	274.5	71.0	-13.8	--
BSE Sensex	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Absci Corp (ABSI)	33.2	-37.4	100.0	-74.4
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Absci Corp (ABSI)	9.0	1,494.8	1.6	-121.1	-7,752.7	-55.6	--	6.6
Arrowhead Pharmaceuticals (ARWR)	82.7	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	71.2	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	55.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	107.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	361.4	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	539.7	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	585.2	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	350.4	9,625.4	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	146.0	9,339.4	282.0	82.9	-28.6	11.4	140.1	11.5

Shareholding Pattern

View Details

About Absci Corp (ABSI)

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory... bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington. Read more

Founder, CEO, President & Director

Mr. Sean McClain
Founder, CEO, President & Director

Mr. Sean McClain
Headquarters

Vancouver, WA
Website

https://www.absci.com

FAQs for Absci Corp (ABSI)

What is the current share price of Absci Corp (ABSI) Today?

The share price of Absci Corp (ABSI) is $8.95 (NASDAQ) as of 01-Sep-2026 11:37 EDT. Absci Corp (ABSI) has given a return of 71% in the last 3 years.

What is the current PB & PE ratio of Absci Corp (ABSI)?

Since, TTM earnings of Absci Corp (ABSI) is negative, P/E ratio is not available.
The P/B ratio of Absci Corp (ABSI) is 6.57 times as on 28-Aug-2026, a 27 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.